Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.

Clin Cancer Res 2017 Aug 26;23(16):4680-4692. Epub 2017 Apr 26.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

Successful development of targeted therapy combinations for cancer patients depends on first discovering such combinations in predictive preclinical models. Stable cell lines and mouse xenograft models can have genetic and phenotypic drift and may take too long to generate to be useful as a personalized medicine tool. To overcome these limitations, we have used a platform of ultra-high-throughput functional screening of primary biopsies preserving both cancer and stroma cell populations from melanoma patients to nominate such novel combinations from a library of thousands of drug combinations in a patient-specific manner within days of biopsy. In parallel, patient-derived xenograft (PDX) mouse models were created and novel combinations tested for their ability to shrink matched PDXs. The screening method identifies specific drug combinations in tumor cells with patterns that are distinct from those obtained from stable cell lines. Screening results were highly specific to individual patients. For patients with matched PDX models, we confirmed that individualized novel targeted therapy combinations could inhibit tumor growth. In particular, a combination of multi-kinase and PI3K/Akt inhibitors was effective in some BRAF-wild-type melanomas, and the addition of cediranib to the BRAF inhibitor PLX4720 was effective in a PDX model with mutation. This proof-of-concept study demonstrates the feasibility of using primary biopsies directly for combinatorial drug discovery, complementing stable cell lines and xenografts, but with much greater speed and efficiency. This process could potentially be used in a clinical setting to rapidly identify therapeutic strategies for individual patients. .

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-3029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559310PMC
August 2017
22 Reads

Publication Analysis

Top Keywords

drug combinations
12
cell lines
12
stable cell
12
primary biopsies
8
ultra-high-throughput functional
8
individual patients
8
novel combinations
8
combinations
8
functional screening
8
targeted therapy
8
therapy combinations
8
patients
5
distinct stable
4
patterns distinct
4
tumor cells
4
identifies specific
4
specific drug
4
lines screening
4
combinations tumor
4
cells patterns
4

Similar Publications